Relative sensitivity and preference of indicators in pharmaceutical trials of psoriasis and psoriatic arthritis.
Discover the optimal indicators for evaluating psoriasis and psoriatic arthritis trials. PASI 50, PASI 75, and IGA 0,1 shine as robust measures, while PASI 125, DIQI 0,1, and NRS-4 fall short. Unlock the power of evidence-based endpoint selection for more effective clinical tr...
This study systematically evaluated the preference and relative sensitivity of the most widely used indicators for reporting response rates in randomized controlled trials (RCTs) of psoriasis (Pso) and psoriatic arthritis (PsA). Using a Bayesian hierarchical linear mixed model, the researchers assessed the differences between control and intervention groups, and ranked the indicators based on their discriminative ability. The findings suggest that PASI 50, PASI 75, and IGA 0,1 are robust indicators for Pso trials, while PASI 50, PASI 75, and PASI 90 are highly effective for PsA trials. However, ACR 20 is recommended to prevent overestimating the therapeutic benefits of interventions in PsA trials. The choice of indicators was influenced by disease severity, intervention type, and administration method. These insights can guide the selection of primary endpoints for more informative and reliable Pso